Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Public Health. 2019 Feb;167:136-146. doi: 10.1016/j.puhe.2018.10.015. Epub 2019 Jan 18.
Herpes zoster (HZ) is an important cause of morbidity around the world, especially among the adult population aged >50 years.
A systematic review of the literature (up to October 31, 2016) was performed to identify available evidence on incidence of HZ in the general population and in a specific subpopulation in Spain.
PubMed and Embase databases were searched, combining the following search terms: 'herpes zoster', 'diabetes mellitus (DM)', 'chronic obstructive pulmonary disease (COPD)', 'chronic heart failure', 'mental disorders' and 'immunocompromised'. Supplements for local scientific congresses, non-indexed Spanish journals and official epidemiological reports, potentially HZ related, were also manually searched. The inclusion criteria were the following: English or Spanish publications reporting incidence of HZ in the Spanish general population and/or specific subpopulations. No restrictions were applied on the study design or population age.
Among 269 references retrieved (48 PubMed, 148 Embase and 73 manual searching), 34 were finally included. Incidence of HZ in the general population ranged from 2.1 to 5.5/1000 person-years. HZ incidence ranged from 9.4 to 15.3/1000 patients with DM and from 11.0 to 11.4/1000 population with COPD or cardiovascular disease. In asthmatic patients, 6.9 HZ cases/1000 subjects were reported. The highest HZ incidence (1.3-400.0/1000 person-years) was in immunocompromised persons (10.0/1000 patients with cancer, 12.5/1000 patients with AIDS, from 5.0 to 240.0/1000 transplanted patients and from 6.6 to 27.0/1000 population with rheumatic diseases). Three studies estimated an increased risk of HZ in comparison with general population, for patients with DM (24%), COPD (39%) and COPD receiving inhaled corticosteroids (61%).
The results suggest a high risk of HZ in certain age groups and specific subpopulations. This study could contribute to identify target age populations and at-risk groups if implementation of HZ vaccination programmes in Spain would be considered.
带状疱疹(HZ)是全球发病率的重要原因,尤其是在 50 岁以上的成年人群中。
对截至 2016 年 10 月 31 日的文献进行系统评价,以确定在西班牙一般人群和特定亚人群中 HZ 发病率的现有证据。
检索 PubMed 和 Embase 数据库,结合以下搜索词:“带状疱疹”、“糖尿病(DM)”、“慢性阻塞性肺疾病(COPD)”、“慢性心力衰竭”、“精神障碍”和“免疫功能低下”。还手动搜索了与 HZ 相关的当地科学大会补充资料、非索引西班牙期刊和官方流行病学报告。纳入标准为:报告西班牙一般人群和/或特定亚人群中 HZ 发病率的英文或西班牙文出版物。对研究设计或人群年龄没有限制。
在检索到的 269 篇参考文献中(48 篇来自 PubMed,148 篇来自 Embase,73 篇来自手动搜索),最终有 34 篇被纳入。一般人群中 HZ 的发病率为 2.1 至 5.5/1000 人年。DM 患者的 HZ 发病率为 9.4 至 15.3/1000 例,COPD 或心血管疾病患者的发病率为 11.0 至 11.4/1000 例。在哮喘患者中,报告了 6.9 例 HZ 病例/1000 例患者。免疫功能低下者的 HZ 发病率最高(1.3-400.0/1000 人年)(10.0/1000 例癌症患者、12.5/1000 例 AIDS 患者、5.0 至 240.0/1000 例移植患者和 6.6 至 27.0/1000 例风湿性疾病患者)。有 3 项研究估计与一般人群相比,DM(24%)、COPD(39%)和 COPD 接受吸入皮质类固醇(61%)患者发生 HZ 的风险增加。
这些结果表明,在某些年龄组和特定亚人群中 HZ 的风险很高。如果考虑在西班牙实施 HZ 疫苗接种计划,本研究可以有助于确定目标年龄人群和高危人群。